
Homozygous deletion (HD) of CDKN2A and CDKN2B (CDKN2A/BHD) is the most frequent copy‐number variation (CNV) in lung adenocarcinoma (LUAD). CDKN2A/BHD has been associated with poor outcomes in LUAD. However, the mechanisms of its prognostic effect remain unknown. The present study analyzed genome, transcriptome, and clinical data from 517 patients with LUAD from the Cancer Genome Atlas (TCGA) and 788 primary LUAD tumor. In addition, it matched control samples from the MSK‐IMPACT clinical cohort. Patients with co‐occurring CDKN2A/BHD and IFN‐IHD had shorter, disease-free, and overall survival than CDKN2A/BWT patients. In addition, CDKN2A/BHDIFN‐IHD had down‐regulated several key immune response pathways, suggesting that poor prognosis in CDKN2A/BHD LUAD could be attributed to an immunosuppressive tumor microenvironment as a result of IFN‐I depletion.
Like
Save
Share